Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.

Print   Email View: All Filings Annual Quarterly Current Section 16 Proxy Other    Year: All Years 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 Filing Description Date Filed Size   4 blickenstaff, kim d Jul 14, 2010 19.8 KB 4 adams, daniel Jul 14, 2010 19.8 KB 4 vernon, w anthony Jul 14, 2010 19.8 KB 4 bailey, gregory Jul 14, 2010 19.8 KB 8-K current report Jun 17, 2010 21.4 KB SC 13G/A amended statement of beneficial ownership May 19, 2010 114.2 KB 4 palekar, rohan May 18, 2010 19.5 KB SC 13G statement of beneficial ownership May 17, 2010 47.3 KB 10-Q quarterly report May 10, 2010 409.3 KB 8-K current report May 10, 2010 73.8 KB DEF 14A definitive proxy statement Apr 30, 2010 401.5 KB CT ORDER confidential treatment order Apr 20, 2010 7.7 KB 8-K current report Mar 29, 2010 26.5 KB 8-K current report Mar 15, 2010 73.6 KB 10-K annual report Mar 15, 2010 2.2 MB SC 13G statement of beneficial ownership Mar 12, 2010 15.9 KB 8-K current report Mar 10, 2010 21.1 KB SC 13G statement of beneficial ownership Mar 5, 2010 58.1 KB 8-K current report Mar 3, 2010 56.4 KB 4 bailey, gregory Feb 23, 2010 19.4 KB Showing 1-20 of 500 Page: 1 2 3 ... 25  Next 20 = add filing to Briefcase